摘要
类风湿关节炎(rheumatoid arthritis, RA)是一种自身免疫性疾病,会引发关节炎症和疼痛,损害关节功能并可引起畸形。迄今没有彻底治愈RA的方法,磷脂酰肌醇3激酶(PI3K)/蛋白激酶B(Akt)信号通路被认为是防治RA的重要途径。PI3K/Akt信号通路涉及细胞的生存、增殖、炎症反应等多个生物学过程。它在RA的发展中扮演了关键角色,它可通过调节炎症介质的产生、影响细胞自噬、破骨细胞的分化、调节细胞凋亡、介导细胞迁移和浸润、调节血管生成和通透性等方面。调节该信号通路将有助于控制炎症、减缓关节损害、促进组织修复,从而改善患者的生活质量。针对PI3K/Akt信号通路的药物研发是探索有效防治RA的一种重要途径。笔者通过查阅大量文献报道,阐述了PI3K/Akt信号通路在RA发生发展中作用的研究进展,旨为未来深入了解RA发病机制和新药物、新治疗方法的开发提供启示,更是为未来临床实践和研究提供参考。
Rheumatoid arthritis(RA)is an autoimmune disease that causes joint inflammation and pain,impairs joint function,and causes deformity.To date,there is no complete cure for RA.The phosphatidylinositol 3-kinase(PI3K)/protein kinase B(Akt)signaling pathway has been identified as an important pathway for the prevention and treatment of RA.The PI3K/Akt signaling pathway is involved in a number of biological processes,including cell survival,proliferation,and inflammatory responses.It plays a key role in the development of RA by regulating the production of inflammatory mediators,influencing cellular autophagy and osteoclast differentiation,regulating apoptosis,mediating cell migration and infiltration,and regulating angiogenesis and permeability.Modulation of this signaling pathway may help to control inflammation,to slow down joint damage,and to promote tissue repair,thus improving patients’quality of life.Drug development targeting to PI3K/Akt signaling pathway is an important way to explore effective prevention and treatment of RA.By reviewing a large number of literature reports,this paper describes the research progress of the role of PI3K/Akt signaling pathway in the development of RA,with the aim of providing insight into the pathogenesis of RA and the development of new drugs and treatments in the future,and even more,to provide reference for future clinical practice and research.
作者
李辉明
邢涛
魏国俊
田雪梅
李盛华
王志勇
薄双娟
LI Huiming;XING Tao;WEI Guojun;TIAN Xuemei;LI Shenghua;WANG Zhiyong;BO Shuangjuan(Gansu Provincial Hospital of TCM,Lanzhou 730050,China)
出处
《中国骨质疏松杂志》
CAS
CSCD
北大核心
2024年第7期1060-1066,共7页
Chinese Journal of Osteoporosis
基金
甘肃省自然科学基金(22JR5RA628,23JRRA1679)
甘肃省中医药科研课题(GZKP-2022-13)。